scholarly journals Studies on Carcinostatic Substances. XL. Application of Cell Counting Method to the Screening of Antitumor Substances using the in vitro-cultured Yoshida Sarcoma Cells.

1962 ◽  
Vol 10 (6) ◽  
pp. 462-467 ◽  
Author(s):  
Ayako Moriwaki
Keyword(s):  
Cell Counting ◽  
Yoshida Sarcoma ◽  
Counting Method ◽  
Sarcoma Cells

scholarly journals Studies on Carcinostatic Substances. XX. Studies on the Culture of Yoshida Sarcoma Cells in vitro.

1959 ◽  
Vol 7 (6) ◽  
pp. 690-694
Author(s):  
Morizo Ishidate ◽  
Yoshio Sakurai ◽  
Hiroshi Imamura ◽  
Ayako Moriwaki
Keyword(s):  
Yoshida Sarcoma ◽  
Sarcoma Cells

scholarly journals Studies on Carcinostatic Substances. XXII. Screening Method for Antimitotic Substance using the in vitro-Cultured Yoshida Sarcoma Cells.

1959 ◽  
Vol 7 (8) ◽  
pp. 873-877 ◽  
Author(s):  
Morizo Ishidate ◽  
Yoshio Sakurai ◽  
Hiroshi Imamura ◽  
Ayako Moriwaki
Keyword(s):  
Screening Method ◽  
Yoshida Sarcoma ◽  
Sarcoma Cells

On the Role of Transferrin in 67Ga Uptake by Tumor Cells

1988 ◽  
Vol 27 (04) ◽  
pp. 151-153
Author(s):  
P. Thouvenot ◽  
F. Brunotte ◽  
J. Robert ◽  
L. J. Anghileri
Keyword(s):  
Specific Binding ◽  
Subcellular Fractionation ◽  
Animal Blood ◽  
Tumor Bearing ◽  
Cell Structures ◽  
The Difference ◽  
Sarcoma Cells ◽  
In Vitro Uptake

In vitro uptake of 67Ga-citrate and 59Fe-citrate by DS sarcoma cells in the presence of tumor-bearing animal blood plasma showed a dramatic inhibition of both 67Ga and 59Fe uptakes: about ii/io of 67Ga and 1/5o of the 59Fe are taken up by the cells. Subcellular fractionation appears to indicate no specific binding to cell structures, and the difference of binding seems to be related to the transferrin chelation and transmembrane transport differences

OSI-027 alleviates oxaliplatin chemoresistance in gastric cancer cells by suppressing P-gp induction

2020 ◽  
Vol 20 ◽  
Author(s):  
En Xu ◽  
Hao Zhu ◽  
Feng Wang ◽  
Ji Miao ◽  
Shangce Du ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cell Cycle ◽  
Cancer Cells ◽  
Mammalian Target Of Rapamycin ◽  
Cell Counting ◽  
Gastric Cancer Cells ◽  
Ags Cells ◽  
Dual Inhibitor ◽  
Induced Apoptosis

: Gastric cancer is one of the most common malignancies worldwide and the third leading cause of cancer-related death. In the present study, we investigated the potential activity of OSI-027, a potent and selective mammalian target of rapamycin complex 1/2 (mTOR1/2) dual inhibitor, alone or in combination with oxaliplatin against gastric cancer cells in vitro. Cell counting kit-8 assays and EdU staining were performed to examine the proliferation of cancer cells. Cell cycle and apoptosis were detected by flow cytometry. Western blot was used to detect the elements of the mTOR pathway and Pgp in gastric cancer cell lines. OSI-027 inhibited the proliferation of MKN-45 and AGS cells by arresting the cell cycle in the G0/G1 phase. At the molecular level, OSI-027 simultaneously blocked mTORC1 and mTORC2 activation, and resulted in the downregulation of phosphor-Akt, phpspho-p70S6k, phosphor-4EBP1, cyclin D1, and cyclin-dependent kinase4 (CDK4). Additionally, OSI-027 also downregulated P-gp, which enhanced oxaliplatin-induced apoptosis and suppressed multidrug resistance. Moreover, OSI-027 exhibited synergistic cytotoxic effects with oxaliplatin in vitro, while a P-gp siRNA knockdown significantly inhibited the synergistic effect. In summary, our results suggest that dual mTORC1/mTORC2 inhibitors (e.g., OSI-027) should be further investigated as a potential valuable treatment for gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document